Alzheimer's drug shows long-term benefits in behavior and cognition. EU approval of Blarcamesine could boost its market value ...

Some of it is in the new Boston home of Eli Lilly & Co ., a $700 million research and development facility along Fort Point ...

Healthcare Opportunities Fund seems to offer a solid balance of capital stability and income. Read why THQ CEF is a Hold.

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

Shares of Eli Lilly & Co. LLY advanced 2.48% to $733.29 Thursday, on what proved to be an all-around great trading session ...

This week's dividend activity included increased payouts from Pepsico (NASDAQ:PEP) and KLA (KLAC) as well as declarations ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even ...

American Medical Association named John J. Whyte, MD, MPH as its next CEO and EVP, effective July 1. Centivo hired Sarah ...